Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

Overview
This review compares how clinical-grade tumor-infiltrating lymphocytes (TIL), CAR or TCR T cells and virus-specific T cells are manufactured under cGMP, from about 6-8 weeks for TIL to roughly 2 weeks for a semi-closed CAR T platform. In G-Rex® bioreactors, T cells specific for five viruses reach a therapeutic dose in roughly 10 days.
What this paper found
Clinical-grade tumor-infiltrating lymphocytes, gene-engineered CAR or TCR T cells and virus-specific T cells can each be manufactured at scale under cGMP, but the processes differ greatly in length and complexity. This review describes standard TIL manufacture, which takes about 6–8 weeks, including a 2-week rapid expansion with irradiated feeder cells, anti-CD3 antibody and 6000 U/mL IL-2. A semi-closed CAR-T platform using Dynabeads, retroviral transduction and a WAVE bioreactor takes about 2 weeks. A CD8 central memory lentiviral platform yields over 1 billion cells within 35 days. Penta-viral-specific T cells grown in G-Rex® bioreactors reach therapeutic doses in about 10 days, versus 10 weeks with traditional methods. The review also covers vector production, process validation and release testing.
Note: Narrative review of published manufacturing methods, focused on phase I/II clinical-trial settings.
Application of ACT has been constrained by the ability to isolate and expand functional tumor-reactive T cells. — X Wang, I Rivière, Cancer Gene Therapy
Study details
- Authors
- X Wang, I Rivière
- Institution
- Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA · Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA · Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Journal
- Cancer Gene Therapy
- Year
- 2015
- Cell type(s)
- CAR T Cells, TCR T Cells, TIL Cells, VST Cells
- Application area
- Hematologic malignancy · Infectious disease · Solid tumor
Explore related
Full citation
Wang X, Rivière I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015;22(2):85-94.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.